About us

Algeta is working to extend and improve cancer patients’ lives by developing targeted therapies to fulfil unmet medical needs.

Algeta is an oncology company seeking to bring novel targeted medicines to patients through its leadership in alpha-pharmaceuticals.

Algeta was founded in 1997. Since then Algeta has developed expert capabilities in its operational areas of research and development, manufacturing, clinical, and commercial. With global clinical operations, it has also established a subsidiary in the US to carry out the co-promotion of its lead product Xofigo (radium Ra 223 dichloride), as part of its 2009 agreement with Bayer.

"Our goal is to develop cancer therapies where there are clear, unmet medical needs"

Our Heritage

Algeta has successfully combined cutting-edge research with commercial know-how.

Read more

Our Research

Combining expertise in radiochemistry, nuclear medicine, and medical oncology, Algeta is at the forefront of alpha-pharmaceutical research.

Read more

Contact us

If you'd like to know more about Algeta and our research, please do get in touch – we'd love to hear from you.

Get in touch